Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.51 |
| ▸ | MAOA | P21397 | 4/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL904863 | 0.90 | MAOB (0.41) | MAOBMAOAPTPN1PTGS2ALDH1A1 | |
| SCHEMBL14270018 | 0.83 | MAOB (0.50) | MAOBMAOAPTPN1PTGS2ALDH1A1 | |
| SCHEMBL28590304 | 0.79 | PTPN1 (0.59) | MAOBMAOAPTPN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL28988609 | 0.79 | PTPN1 (0.59) | MAOBMAOAPTPN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL15536620 | 0.78 | MAOB (0.49) | MAOBMAOAPTPN1PTGS2ALDH1A1 | |
| SCHEMBL28600756 | 0.77 | MAPT (0.45) | MAOBMAOAPTPN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL25442218 | 0.76 | CYP11B1 (0.48) | MAOBMAOAPTPN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL28594851 | 0.76 | PTPN1 (0.56) | MAOBMAOAPTPN1ALDH1A1HSD17B10 | |
| SCHEMBL18878405 | 0.76 | PTPN1 (0.56) | MAOBMAOAPTPN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL28600768 | 0.76 | MAPT (0.44) | MAOBMAOAPTPN1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115974825-A | Method for preparing 3-substituted chromanone through metal-free catalytic hydrogenation | 中国科学院化学研究所 | 2023-04-18 | — | — | CN | disclosed |
| US-11530209-B2 | Small molecule inhibition of transcription factor SALL4 and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| CN-112898259-B | Method for preparing 3-substituted chromanone through nonmetal catalytic hydrogenation | 中国科学院化学研究所 | 2022-05-17 | — | — | CN | disclosed |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| WO-2021143753-A1 | ATX INHIBITOR BASED ON INDOLE MOTHER NUCLEUS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 沈阳药科大学 | 2021-07-22 | — | — | WO | disclosed |
| CN-112898259-A | Method for preparing 3-substituted chromanone through nonmetal catalytic hydrogenation | 中国科学院化学研究所 | 2021-06-04 | — | — | CN | disclosed |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200317664-A1 | SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-10-08 | — | — | US | disclosed |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200102264-A1 | MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT | THE UNIVERSITY OF KANSAS (US) | 2020-04-02 | — | — | US | disclosed |
| US-8008499-B2 | Anabaseine derivatives, pharmaceutical compositions and methods of use thereof | CORNERSTONE THERAPEUTICS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100311773-A1 | NOVEL ANABASEINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | Cornerstone Therapeutic, Inc. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7662965-B2 | 3-(3-(2,5-dichlorophenyl)furan-2-yl)methylene)-3,4,5,6-tetrahydropyridin-2-yl)pyridine; antiinflammatory agent for inhibiting cytokine release from mammalian cells; treating CNS disorders; agonists of nicotinic acetylcholine receptors | CORNERSTONE THERAPEUTICS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20080176815-A1 | Compounds that interact with kinases | ALCHEMIA LIMITED (AU) | 2008-07-24 | — | — | US | disclosed |
| US-20080070916-A1 | Dihydropyrancarboxamides and uses thereof | SCHREIBER STUART L | 2008-03-20 | — | — | US | disclosed |
| US-20080070916-A1 | Dihydropyrancarboxamides and uses thereof | SCHREIBER STUART L | 2008-03-20 | — | — | US | disclosed |
| US-7291623-B2 | Compounds that interact with kinases | ALCHEMIA LIMITED (AU) | 2007-11-06 | — | — | US | disclosed |
| US-20070232651-A1 | Novel anabaseine derivatives, pharmaceutical compositions and methods of use thereof | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH | 2007-10-04 | — | — | US | disclosed |
| US-7186709-B2 | Subjecting a vinyl ethers and an unsaturated ketoester to suitable conditions to generate a scaffold having the core dihydropyrancarboxamide or dihydropyrancarboxylic ester or acid; anticarcinogenic agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186709-B2 | Subjecting a vinyl ethers and an unsaturated ketoester to suitable conditions to generate a scaffold having the core dihydropyrancarboxamide or dihydropyrancarboxylic ester or acid; anticarcinogenic agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102264-A1 | MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT | COIL, MUC1, MAN2B2 | MAOB 2464/4885MAOA 2623/4885PTPN1 1334/4885 |
| US-20070232651-A1 | Novel anabaseine derivatives, pharmaceutical compositions and methods of use thereof | CHRNA7, CHRNA10, CHRNA5 | MAOB 241/4885MAOA 636/4885PTPN1 3529/4885 |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | CHUK, BCOR, MYC | MAOB 4012/4885MAOA 4207/4885PTPN1 1552/4885 |
| US-20080070916-A1 | Dihydropyrancarboxamides and uses thereof | CCNA1, DPYD, DHFR | MAOB 1529/4885MAOA 2073/4885PTPN1 3577/4885 |
| US-20080176815-A1 | Compounds that interact with kinases | MAP3K6, MAP3K20, MAP4K2 | MAOB 3847/4885MAOA 3933/4885PTPN1 548/4885 |
| US-20100311773-A1 | NOVEL ANABASEINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CHRNA7, CHRNA10, CHRNA5 | MAOB 241/4885MAOA 636/4885PTPN1 3529/4885 |
| US-11530209-B2 | Small molecule inhibition of transcription factor SALL4 and uses thereof | SALL4, GLI2, TCF4 | MAOB 4460/4885MAOA 4614/4885PTPN1 2601/4885 |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | MAOB 2073/4885MAOA 2496/4885PTPN1 2295/4885 |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | MAOB 4012/4885MAOA 4207/4885PTPN1 1552/4885 |
| US-20200317664-A1 | SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF | SALL4, GLI2, TCF4 | MAOB 4460/4885MAOA 4614/4885PTPN1 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.